Press Release

This partnership will help biomedical researchers access and analyze data from Singular Genomics systems and easily collaborate on the cloud using a secure, scalable and open source informatic platform

LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the company is collaborating with the Broad Institute of MIT and Harvard to connect the Singular Genomics G4 sequencer to Terra, a data platform co-developed by the Broad Institute, Microsoft and Verily that connects researchers to each other and to the datasets and tools they need to achieve scientific breakthroughs. This integration between the two platforms will give researchers using the G4 sequencer seamless access to cloud-based data storage and analytical tools optimized for genomic data.

“We are thrilled to bring Terra’s advanced bioinformatic platform to Singular Genomics customers as a plug-and-play bioinformatics solution,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “To complement and leverage the G4’s accuracy, speed, flexibility and power, Terra will provide our customers with a seamless solution for secondary and tertiary analysis, data storage, and data sharing. We anticipate this will be the first of many exciting expanded offerings for G4.”

“With Terra, researchers are more easily and seamlessly able to develop insights from vast amounts of data and advance biomedical research,” said Clare Bernard, Senior Director of the Data Sciences Platform at the Broad Institute. “We are pleased to facilitate access to Terra as a comprehensive bioinformatic platform for Singular Genomics customers.”

About Terra
Terra, developed by the Broad Institute, Microsoft and Verily is a secure, scalable, open-source platform for biomedical researchers to access data, run analysis tools and collaborate. Terra is actively used by thousands of researchers every month to analyze data from millions of participants in scientific research projects.

For more information about Terra, visit https://terra.bio.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products in development as well as our core product tenets: accuracy, speed, flexibility and scale. We are currently developing two integrated solutions that are purpose built to target applications in which these core product tenets matter most. Our first integrated solution, the G4 sequencing platform, is targeted at the NGS market. Our second integrated solution in development, the PX Integrated Solution, combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution. The G4 and PX sequencing platforms are both comprised of an instrument and an associated menu of consumable kits.

Forward-Looking Statements
Certain statements contained in this press release, other than historical information, may constitute forward-looking statements within the meaning of the Federal securities laws. Any such forward-looking statements are based on our management’s current expectations and are subject to a number of risks and uncertainties that could cause our actual future results to differ materially from our management’s current expectations or those implied by the forward-looking statements. These risk factors that may affect our future results of operations are identified and described in more detail in our filings with the SEC, including our Quarterly Report on Form 10-Q for period ended September 30, 2021, filed with the SEC on November 9, 2021. Accordingly, you should not rely upon forward-looking statements as predictions of future events or our future performance. Except as required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com